8-K
filed June 2, 2023, 7:59 PM ET
ticker ACAD
CIK 0001070494
other material
confidence high
sentiment neutral
materiality 0.15
Acadia shareholders elect three Class I directors, approve say-on-pay, and ratify EY as auditor on annual basis
ACADIA PHARMACEUTICALS INC
- Elected James M. Daly, Edmund P. Harrigan, and Adora Ndu as Class I directors (for votes: 108.2M, 126.2M, 131.6M).
- Advisory say-on-pay approved with 87.3M for vs. 48.3M against; broker non-votes 9.9M.
- Stockholders favored annual advisory vote on executive compensation (135.1M votes for 1 year); board adopts annual frequency.
- Ratification of Ernst & Young as independent auditor for FY2023 approved (144.9M for, 0.5M against, 0.1M abstain).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2023-06-01 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
The following three Class I directors were elected by the votes indicated: For Withheld Broker Non- Votes James M. Daly 108,235,140 27,416,787 9,880,431 Edmund P. Harrigan 126,226,342 9,425,585 9,880,431 Adora Ndu 131,558,098 4,093,829 9,880,431
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-01 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
the indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, which received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 135,140,475 54,863 345,208 111,380 9,880,432
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the following vote: For Against Abstain 144,928,829 466,591 136,938
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-01 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2023, which was approved by the following vote: For Against Abstain Broker Non-Votes 87,274,917 48,257,939 119,071 9,880,431
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.